Physician profile
Bryan M Kahl
NPI 1508905837
$11,209.14
in general payments reported to CMS, 2019-2025
41 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,469 · 2020: $1,803 · 2021: $259 · 2022: $805 · 2023: $1,830 · 2024: $2,476 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,037 · Travel and Lodging: $812 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,037.42 |
| Travel and Lodging | $811.70 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,382.47 | 2022-2024 | Minimed 780g, Intellis Adaptivestim |
| Amgen INC. | $1,086.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,005.83 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $846.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.13 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $655.33 | 2019-2023 | Farxiga |
| Abbvie INC. | $628.76 | 2019-2025 | |
| Corcept Therapeutics | $529.15 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $528.51 | 2019-2022 | |
| Insulet Corporation | $519.60 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $384.40 | 2022-2025 | Gvoke Hypopen |
| Dexcom, INC. | $373.24 | 2019-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $328.22 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $263.90 | 2019-2021 | |
| Radius Health, INC. | $262.85 | 2019-2025 | Tymlos |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $230.67 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $181.85 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $175.52 | 2019-2025 | Tirosint, Tirosint, Licart |
| Neurocrine Biosciences, INC. | $173.43 | 2025 | |
| Abbott Laboratories | $152.57 | 2020-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $91.54 | 2023-2024 | Unithroid |
| Ascendis Pharma Endocrinology INC | $77.94 | 2023-2025 | Yorvipath |
| Shire North American Group INC | $77.77 | 2019 | |
| Beta Bionics, INC. | $73.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $61.65 | 2024-2025 | Xyosted |
| Esperion Therapeutics, INC. | $53.91 | 2022-2025 | Nexletol |
| Amarin Pharma, INC. | $46.45 | 2019-2022 | |
| Amphastar Pharmaceuticals, INC. | $34.82 | 2024 | |
| Pfizer INC. | $34.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.04 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $32.43 | 2022-2023 | |
| Becton, Dickinson and Company | $24.02 | 2019 | |
| Ascensia Diabetes Care US INC. | $23.43 | 2024 | |
| Sequel Med Tech, LLC | $23.34 | 2025 | Twiist |
| Kyowa Kirin, INC. | $23.16 | 2023 | Crysvita |
| Astellas Pharma US INC | $18.37 | 2025 | Veozah |
| Acerus Pharmaceuticals Corporation | $18.04 | 2022 | |
| Medtronic Minimed, INC. | $16.53 | 2020 | |
| Glaxosmithkline, LLC. | $15.38 | 2025 | Arexvy |
| Rhythm Pharmaceuticals, INC. | $14.64 | 2025 | Imcivree |
| Rgh Enterprises LLC | $14.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.